Oxford, UK, 26 April 2022 – Argonaut Therapeutics, a leading developer of novel cancer agents, gave a company showcase presentation at the BioTrinity 2022 event, an international conference focused on bio-partnering and investment. The presentation to an audience of key…
Oxford, UK, 7 April 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a Phase I clinical trial cancer patient who continues to benefit from continuous zabadinostat therapy for over 2 years. CXD101-0901 is…
Oxford UK, 20 January 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a 14.5% patient two-year survival rate following treatment in their Phase II clinical trial testing the immune check point inhibitor (ICI)…
Oxford, UK, 30 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the adoption of a precision medicine biomarker platform in its registrational immune combination therapy study in colorectal cancer patients. CAROSELL Clinical Study…
Oxford, UK, 8 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the appointment of Dr Katherine Innes-Ker to its Board of Directors. Dr Katherine Innes Ker BA (Hons), DPhil, has been appointed…
Oxford, UK, 27th Sep 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the appointment of Richard Taylor to its Board of Directors. Richard Taylor MA ACMA has been appointed as a Non-Executive Director…
Oxford, August 25, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, today announced that it has appointed Mr James Noble as its new Board Chairman. James Noble MA FCA has held a number of high-profile…
Oxford, UK, 6th July 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced encouraging early clinical data from its Hong Kong Phase I study to develop CXD101 in patients suffering from peripheral T-cell lymphoma (PTCL),…
Oxford, April 2nd, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, has worked closely with Oxford University’s Medical Sciences Division to investigate the mechanism of action of zabinostat (previously known as CXD101). The study found…
Oxford, March 1st, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, will be represented by its Chief Medical Officer, Professor David Kerr, at the WuXi Healthcare Forum 2021. The second annual WuXi Healthcare Forum will…